2025 United Kingdom Anti-Asthma Drugs Market Revenue Opportunities Report
Description
The 2025 United Kingdom Anti-Asthma Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Asthma Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the UK anti-asthma drugs market are GlaxoSmithKline (GSK), AstraZeneca, Merck & Co., and Novartis. GSK, headquartered in London, is a leader in severe asthma treatment with biologics such as depemokimab, targeting severe eosinophilic asthma with a convenient 6-month dosing schedule, enhancing patient adherence. AstraZeneca, based in Cambridge, UK, offers innovative therapies like Airsupra, an anti-inflammatory rescue treatment reducing severe exacerbations, and is a major player in the UK respiratory market. Merck & Co. is globally significant in asthma drug development and commercializes biologics for severe asthma; it maintains a robust presence in the UK pharmaceutical landscape.
Novartis, with a strong global portfolio including monoclonal antibodies and small molecules, actively competes in the UK market addressing both inflammation and airway obstruction in asthma patients. These companies are investing heavily in biologic therapies and combination inhalers to improve long-term asthma control and patient outcomes, driving market growth in the UK valued at over $876 million in 2023 and expected to exceed $1.14 billion by 2030. Their ongoing research, acquisitions, and product launches firmly position them as market leaders in advancing asthma therapeutics.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Asthma Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the UK anti-asthma drugs market are GlaxoSmithKline (GSK), AstraZeneca, Merck & Co., and Novartis. GSK, headquartered in London, is a leader in severe asthma treatment with biologics such as depemokimab, targeting severe eosinophilic asthma with a convenient 6-month dosing schedule, enhancing patient adherence. AstraZeneca, based in Cambridge, UK, offers innovative therapies like Airsupra, an anti-inflammatory rescue treatment reducing severe exacerbations, and is a major player in the UK respiratory market. Merck & Co. is globally significant in asthma drug development and commercializes biologics for severe asthma; it maintains a robust presence in the UK pharmaceutical landscape.
Novartis, with a strong global portfolio including monoclonal antibodies and small molecules, actively competes in the UK market addressing both inflammation and airway obstruction in asthma patients. These companies are investing heavily in biologic therapies and combination inhalers to improve long-term asthma control and patient outcomes, driving market growth in the UK valued at over $876 million in 2023 and expected to exceed $1.14 billion by 2030. Their ongoing research, acquisitions, and product launches firmly position them as market leaders in advancing asthma therapeutics.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
